Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

ARDT vs DBVT vs HCA vs ALKS vs MCK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ARDT
Ardent Health Partners, LLC

Medical - Care Facilities

HealthcareNYSE • US
Market Cap$1.41B
5Y Perf.-44.7%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.+230.4%
HCA
HCA Healthcare, Inc.

Medical - Care Facilities

HealthcareNYSE • US
Market Cap$95.95B
5Y Perf.+18.2%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+29.6%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$92.15B
5Y Perf.+21.9%

ARDT vs DBVT vs HCA vs ALKS vs MCK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ARDT logoARDT
DBVT logoDBVT
HCA logoHCA
ALKS logoALKS
MCK logoMCK
IndustryMedical - Care FacilitiesBiotechnologyMedical - Care FacilitiesBiotechnologyMedical - Distribution
Market Cap$1.41B$1712.35T$95.95B$5.90B$92.15B
Revenue (TTM)$6.43B$0.00$75.60B$1.56B$403.43B
Net Income (TTM)$134M$-168M$6.78B$153M$4.76B
Gross Margin60.5%41.5%65.4%3.6%
Operating Margin8.9%15.8%12.3%1.5%
Forward P/E8.7x14.2x24.8x19.3x
Total Debt$2.26B$22M$50.20B$70M$7.39B
Cash & Equiv.$710M$194M$1.04B$1.12B$5.69B

ARDT vs DBVT vs HCA vs ALKS vs MCKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ARDT
DBVT
HCA
ALKS
MCK
StockJul 24May 26Return
Ardent Health Partn… (ARDT)10055.3-44.7%
DBV Technologies S.… (DBVT)100330.4+230.4%
HCA Healthcare, Inc. (HCA)100118.2+18.2%
Alkermes plc (ALKS)100129.6+29.6%
McKesson Corporation (MCK)100121.9+21.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: ARDT vs DBVT vs HCA vs ALKS vs MCK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: HCA and MCK are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. McKesson Corporation is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. ARDT, DBVT, and ALKS also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
ARDT
Ardent Health Partners, LLC
The Value Play

ARDT ranks third and is worth considering specifically for value.

  • Lower P/E (8.7x vs 24.8x)
Best for: value
DBVT
DBV Technologies S.A.
The Momentum Pick

DBVT is the clearest fit if your priority is momentum.

  • +110.4% vs ARDT's -30.5%
Best for: momentum
HCA
HCA Healthcare, Inc.
The Income Pick

HCA has the current edge in this matchup, primarily because of its strength in income & stability and long-term compounding.

  • Dividend streak 5 yrs, beta 0.29, yield 0.7%
  • 450.5% 10Y total return vs MCK's 348.1%
  • Beta 0.29, yield 0.7%, current ratio 0.83x
  • 0.7% yield, 5-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend)
Best for: income & stability and long-term compounding
ALKS
Alkermes plc
The Defensive Pick

ALKS is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
  • 9.8% margin vs DBVT's 0.3%
Best for: sleep-well-at-night
MCK
McKesson Corporation
The Growth Play

MCK is the #2 pick in this set and the best alternative if growth exposure and valuation efficiency is your priority.

  • Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
  • PEG 0.49 vs HCA's 0.67
  • 16.2% revenue growth vs DBVT's -100.0%
  • Beta 0.04 vs ARDT's 1.40
Best for: growth exposure and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthMCK logoMCK16.2% revenue growth vs DBVT's -100.0%
ValueARDT logoARDTLower P/E (8.7x vs 24.8x)
Quality / MarginsALKS logoALKS9.8% margin vs DBVT's 0.3%
Stability / SafetyMCK logoMCKBeta 0.04 vs ARDT's 1.40
DividendsHCA logoHCA0.7% yield, 5-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend)
Momentum (1Y)DBVT logoDBVT+110.4% vs ARDT's -30.5%
Efficiency (ROA)HCA logoHCA11.3% ROA vs DBVT's -89.0%

ARDT vs DBVT vs HCA vs ALKS vs MCK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ARDTArdent Health Partners, LLC
FY 2025
Reportable Segment
100.0%$6.3B
DBVTDBV Technologies S.A.

Segment breakdown not available.

HCAHCA Healthcare, Inc.
FY 2025
Managed Care And Other Insurers
50.5%$37.0B
Managed Medicare
18.4%$13.4B
Medicare
15.4%$11.3B
Medicaid
8.1%$5.9B
Managed Medicaid
5.0%$3.7B
International
2.5%$1.9B
ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B

ARDT vs DBVT vs HCA vs ALKS vs MCK — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMCKLAGGINGHCA

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 4 of 6 comparable metrics.

MCK and DBVT operate at a comparable scale, with $403.4B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to MCK's 1.2%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricARDT logoARDTArdent Health Par…DBVT logoDBVTDBV Technologies …HCA logoHCAHCA Healthcare, I…ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
RevenueTrailing 12 months$6.4B$0$75.6B$1.6B$403.4B
EBITDAEarnings before interest/tax$733M-$112M$15.5B$212M$6.8B
Net IncomeAfter-tax profit$134M-$168M$6.8B$153M$4.8B
Free Cash FlowCash after capex$214M-$151M$7.7B$392M$6.0B
Gross MarginGross profit ÷ Revenue+60.5%+41.5%+65.4%+3.6%
Operating MarginEBIT ÷ Revenue+8.9%+15.8%+12.3%+1.5%
Net MarginNet income ÷ Revenue+2.1%+9.0%+9.8%+1.2%
FCF MarginFCF ÷ Revenue+3.3%+10.2%+25.1%+1.5%
Rev. Growth (YoY)Latest quarter vs prior year+7.0%+6.7%+28.2%+6.0%
EPS Growth (YoY)Latest quarter vs prior year-3.4%+91.5%+44.6%-4.1%+37.0%
ALKS leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

ARDT leads this category, winning 4 of 7 comparable metrics.

At 10.3x trailing earnings, ARDT trades at a 65% valuation discount to MCK's 29.2x P/E. Adjusting for growth (PEG ratio), HCA offers better value at 0.72x vs MCK's 0.75x — a lower PEG means you pay less per unit of expected earnings growth.

MetricARDT logoARDTArdent Health Par…DBVT logoDBVTDBV Technologies …HCA logoHCAHCA Healthcare, I…ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
Market CapShares × price$1.4B$1712.35T$95.9B$5.9B$92.1B
Enterprise ValueMkt cap + debt − cash$3.0B$1712.35T$145.1B$4.9B$93.8B
Trailing P/EPrice ÷ TTM EPS10.29x-0.76x15.12x24.76x29.25x
Forward P/EPrice ÷ next-FY EPS est.8.65x14.19x19.28x
PEG RatioP/E ÷ EPS growth rate0.72x0.75x
EV / EBITDAEnterprise value multiple6.17x9.37x17.25x18.74x
Price / SalesMarket cap ÷ Revenue0.22x1.27x4.00x0.26x
Price / BookPrice ÷ Book value/share0.83x0.66x3.28x
Price / FCFMarket cap ÷ FCF5.47x12.47x12.28x17.63x
ARDT leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 4 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARDT's 1.34x. On the Piotroski fundamental quality scale (0–9), HCA scores 7/9 vs DBVT's 4/9, reflecting strong financial health.

MetricARDT logoARDTArdent Health Par…DBVT logoDBVTDBV Technologies …HCA logoHCAHCA Healthcare, I…ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
ROE (TTM)Return on equity+8.0%-130.2%+8.8%+3.0%
ROA (TTM)Return on assets+2.6%-89.0%+11.3%+5.4%+5.7%
ROICReturn on invested capital+7.5%+19.9%+18.9%+5.4%
ROCEReturn on capital employed+7.9%-145.7%+27.0%+14.2%+30.5%
Piotroski ScoreFundamental quality 0–964776
Debt / EquityFinancial leverage1.34x0.13x0.04x
Net DebtTotal debt minus cash$1.6B-$172M$49.2B-$1.0B$1.7B
Cash & Equiv.Liquid assets$710M$194M$1.0B$1.1B$5.7B
Total DebtShort + long-term debt$2.3B$22M$50.2B$70M$7.4B
Interest CoverageEBIT ÷ Interest expense6.36x-189.82x5.37x32.30x33.79x
MCK leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

MCK leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs ARDT's -30.5%. The 3-year compound annual growth rate (CAGR) favors MCK at 27.3% vs ARDT's -15.0% — a key indicator of consistent wealth creation.

MetricARDT logoARDTArdent Health Par…DBVT logoDBVTDBV Technologies …HCA logoHCAHCA Healthcare, I…ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
YTD ReturnYear-to-date+14.4%+4.9%-8.6%+25.3%-8.5%
1-Year ReturnPast 12 months-30.5%+110.4%+19.7%+16.5%+4.6%
3-Year ReturnCumulative with dividends-38.5%+19.7%+57.4%+14.5%+106.4%
5-Year ReturnCumulative with dividends-38.5%-69.1%+109.7%+60.9%+286.9%
10-Year ReturnCumulative with dividends-38.5%-87.0%+450.5%-11.0%+348.1%
CAGR (3Y)Annualised 3-year return-15.0%+6.2%+16.3%+4.6%+27.3%
MCK leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ALKS and MCK each lead in 1 of 2 comparable metrics.

MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than ARDT's 1.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs ARDT's 63.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricARDT logoARDTArdent Health Par…DBVT logoDBVTDBV Technologies …HCA logoHCAHCA Healthcare, I…ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
Beta (5Y)Sensitivity to S&P 5001.40x1.26x0.29x1.06x0.04x
52-Week HighHighest price in past year$15.48$26.18$556.52$36.60$999.00
52-Week LowLowest price in past year$8.07$7.53$330.00$25.17$637.00
% of 52W HighCurrent price vs 52-week peak+63.8%+76.3%+77.1%+96.7%+75.3%
RSI (14)Momentum oscillator 0–10046.648.130.860.216.2
Avg Volume (50D)Average daily shares traded382K252K1000K2.3M757K
Evenly matched — ALKS and MCK each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — HCA and MCK each lead in 1 of 2 comparable metrics.

Analyst consensus: ARDT as "Buy", DBVT as "Buy", HCA as "Buy", ALKS as "Buy", MCK as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 22.9% for HCA (target: $527). For income investors, HCA offers the higher dividend yield at 0.69% vs MCK's 0.36%.

MetricARDT logoARDTArdent Health Par…DBVT logoDBVTDBV Technologies …HCA logoHCAHCA Healthcare, I…ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$13.33$46.33$527.45$44.00$1006.50
# AnalystsCovering analysts1215462831
Dividend YieldAnnual dividend ÷ price+0.7%+0.4%
Dividend StreakConsecutive years of raises105017
Dividend / ShareAnnual DPS$2.94$2.69
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+10.5%+0.5%+3.4%
Evenly matched — HCA and MCK each lead in 1 of 2 comparable metrics.
Key Takeaway

MCK leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). ALKS leads in 1 (Income & Cash Flow). 2 tied.

Best OverallMcKesson Corporation (MCK)Leads 2 of 6 categories
Loading custom metrics...

ARDT vs DBVT vs HCA vs ALKS vs MCK: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ARDT or DBVT or HCA or ALKS or MCK a better buy right now?

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Ardent Health Partners, LLC (ARDT) offers the better valuation at 10. 3x trailing P/E (8. 7x forward), making it the more compelling value choice. Analysts rate Ardent Health Partners, LLC (ARDT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ARDT or DBVT or HCA or ALKS or MCK?

On trailing P/E, Ardent Health Partners, LLC (ARDT) is the cheapest at 10.

3x versus McKesson Corporation at 29. 2x. On forward P/E, Ardent Health Partners, LLC is actually cheaper at 8. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 49x versus HCA Healthcare, Inc. 's 0. 67x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — ARDT or DBVT or HCA or ALKS or MCK?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: HCA returned +450. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ARDT or DBVT or HCA or ALKS or MCK?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus Ardent Health Partners, LLC's 1. 40β — meaning ARDT is approximately 3147% more volatile than MCK relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 134% for Ardent Health Partners, LLC — giving it more financial flexibility in a downturn.

05

Which is growing faster — ARDT or DBVT or HCA or ALKS or MCK?

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: HCA Healthcare, Inc. grew EPS 29. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ARDT or DBVT or HCA or ALKS or MCK?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ARDT leads at 97. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ARDT or DBVT or HCA or ALKS or MCK more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 49x versus HCA Healthcare, Inc. 's 0. 67x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Ardent Health Partners, LLC (ARDT) trades at 8. 7x forward P/E versus 19. 3x for McKesson Corporation — 10. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

08

Which pays a better dividend — ARDT or DBVT or HCA or ALKS or MCK?

In this comparison, HCA (0.

7% yield), MCK (0. 4% yield) pay a dividend. ARDT, DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.

09

Is ARDT or DBVT or HCA or ALKS or MCK better for a retirement portfolio?

For long-horizon retirement investors, HCA Healthcare, Inc.

(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Both have compounded well over 10 years (HCA: +450. 5%, ARDT: -38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ARDT and DBVT and HCA and ALKS and MCK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ARDT is a small-cap deep-value stock; DBVT is a mega-cap quality compounder stock; HCA is a mid-cap deep-value stock; ALKS is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. HCA pays a dividend while ARDT, DBVT, ALKS, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ARDT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 36%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

HCA

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.